Vesalius Biocapital

A European life sciences venture capital investor


About us

Vesalius Biocapital is a European life sciences venture capital investor. The active fund Vesalius Biocapital III had a final closing in May 2019 with € 120 million in commitments.

We are investing in appealing, later-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, predominantly in Europe. Our portfolio companies address unmet medical & market needs and operate on the basis of strong intellectual property protection.


Fund 3

Vesalius Biocapital III

Vintage 2017 - € 120 million assets under management. In investment mode

read more



Vesalius News

CatalYm in Nature Communications
read more
OncoDNA: Closing Round C financing
read more
Memo Therapeutics: U.S. Pivotal Phase II/III
read more